Loading
In CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, the antibody-drug conjugate brentuximab vedotin produced lasting responses in more than half of patients, far more than methotrexate or bexarotene.
Phase 3 trial of 131 patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma previously treated with systemic therapy, randomised to brentuximab vedotin or physician's choice of methotrexate or bexarotene.
Objective response lasting at least four months was 56.3 versus 12.5 percent, median progression-free survival 16.7 versus 3.5 months, and peripheral neuropathy occurred in two thirds of brentuximab patients.
Brentuximab vedotin is a standard for CD30-positive cutaneous T-cell lymphoma requiring systemic therapy, including large cell transformation.
Shares Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America, The Lancet, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares ALCANZA, Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares ALCANZA, Mycosis fungoides, Brentuximab vedotin, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Brentuximab vedotin, The Lancet, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Brentuximab vedotin, The Lancet.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America, Brentuximab vedotin, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.